Jeffrey S Baxter

8217077, Jul 10, 2012

Dec 29, 2004

11/025466

Jeffrey H. Baxter - Gahanna OH, US
Pradip Mukerji - Gahanna OH, US
Anne C. Voss - Columbus OH, US
Michael J. Tisdale - Birmingham, GB

Abbott Laboratories - Abbott Park IL

A61K 31/19

514557

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

8609725, Dec 17, 2013

Jan 11, 2012

13/348026

Jeffrey H. Baxter - Westerville OH, US
Anne C. Voss - Columbus OH, US
Pradip Mukerji - Gahanna OH, US
Michael J. Tisdale - Birmingham, GB

Abbott Laboratories - Abbott Park IL

A61K 31/19
A61K 31/70
A61K 31/355
A61K 31/34
A61K 31/20

514557, 514 23, 514168, 514458, 514474, 514 56 O

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

20030099722, May 29, 2003

Oct 9, 2001

09/973105

Jeffrey Baxter - Galena OH, US

A61K033/14
A61K033/00
A61K031/70
A61K031/495
A61K031/445
A61K031/198

424/679000, 424/680000, 424/722000, 424/717000, 514/023000, 514/252120, 514/315000, 514/554000, 514/563000

Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.

20030129262, Jul 10, 2003

Aug 30, 2002

10/231562

Daniel Epner - Houston TX, US
Jeffrey Baxter - Galena OH, US
Jeffrey Kivi - Westerville OH, US
Robert Hards - Delaware OH, US

A61K038/48
A61K035/78

424/757000, 424/094630

The present invention is directed to methods and compositions regarding induction of apoptosis in a cell and treatment of cancer in an individual wherein methionine deprivation of the cell is followed by methionine repletion of the cell. The methionine deprivation of the cell results in G2 arrest in the cell, leading to DNA damage in the cell. Upon readministration of methionine to the cell, the damaged cell exits G2 arrest and enters into apoptosis. In a specific embodiment, a therapeutic effect is elicited by cycling the patient between a methionine-depleted diet and a normal, methionine-replete diet. The present invention also regards chronic methionine deprivation for treatment of cancer in a human, in addition to methods for methionine restriction as adjunctive therapy for other cancer treatment methods.

20030134851, Jul 17, 2003

Oct 8, 2002

10/266317

Jeffrey Baxter - Galena OH, US
Jose Pedrosa - Granada, ES
Ricardo Cabrera - Granada, ES

A61K031/535
A61K031/497
A61K031/445
A61K031/198

514/231200, 514/563000, 514/252120, 514/315000, 514/537000

Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.

20040081708, Apr 29, 2004

Jul 18, 2003

10/623194

Jeffrey Baxter - Galena OH, US

A61K031/70
A61K031/445
A61K031/205
A61K031/495
A61K031/19
A61K033/00

424/722000, 514/023000, 514/563000, 514/252120, 514/316000, 514/554000, 514/574000

Methods and compositions for providing glutamine supplementation to a human by orally administering an effective amount of N-acetyl-L-glutamine or a nutritionally acceptable salt thereof. The N-acetyl L-glutamine or a nutritionally acceptable salt thereof can be incorporated into any liquid composition that is suitable for human consumption. Examples of suitable compositions include aqueous solutions such as for use as oral rehydration solutions and liquid nutritional formulas (including enteral formulas, oral formulas, formulas for adults, formulas for children and formulas for infants). The quantity of N-acetyl-L-glutamine or nutritionally acceptable salt thereof can vary widely but typically, these compositions will contain sufficient N-acetyl-L-glutamine or a nutritionally acceptable salt thereof to provide at least 140 mg of total glutamine per kg of body weight per day.

20050215640, Sep 29, 2005

Mar 26, 2004

10/810762

Jeffrey Baxter - Gahanna OH, US
Pradip Mukerji - Gahanna OH, US
Anne Voss - Columbus OH, US
Michael Tisdale - Birmingham, GB

A61K031/202

514560000

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

20090005544, Jan 1, 2009

Jun 25, 2008

12/145776

Louis I. Ndife - Columbus OH, US
Chad R. Cole - Blacklick OH, US
Jeffrey H. Baxter - Westerville OH, US

C07K 1/30

530418

Disclosed is a process comprising: mixing a soy protein-containing material with an aqueous medium; removing the non-solubilized solids from the slurry to form an alkaline liquid containing solubilized soy protein; adjusting the pH of the solubilized soy protein liquid to between about 3.8 and about 6.6, to precipitate soy protein from the liquid; separating the precipitated soy protein from the pH-adjusted soy protein liquid; resolubilizing the separated soy protein precipitate in an aqueous medium at a pH of from about 1.8 to 3.2; treating the resolubilized soy protein with at least one water-soluble calcium salt to form a calcium-enriched soy protein mixture; precipitating soy protein from the calcium-enriched soy protein mixture by adjusting the pH of the mixture to between about 3.8 and about 6.6; separating the precipitated soy protein from the calcium-enriched soy protein mixture; and washing to form calcium-enriched soy protein isolate having selectively reduced manganese concentrations.